Bank of America Securities Raises PT on Teva Pharmaceutical Industries (TEVA), Keeps a Buy

​Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 9, Jason Gerberry from Bank of America Securities raised the firm’s price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) from $22 to $24 while keeping a Buy rating on the stock.

​The analyst noted that they previewed their EPS estimates for commercial-stage biotech companies. As per the Q3 pricing volume trends on key drugs, the company does not expect any major beat or miss for Q3 in the sector.

​Earlier on September 25, Teva Pharmaceutical Industries Limited (NYSE:TEVA) released its Aide Mémoires ahead of its Q3 results scheduled for November 5, 2025. As per the report, management expects full-year revenue in the range of $16.8 billion and $17.2 billion, reflecting 2% to 4% increase year-over-year. The outlook is in line with the general consensus of $16.901 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is an international drug maker that sells a range of generic, specialty, and OTC products.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.